7 Drugs Approved for Primary Care: Q4 2024
An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.
Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds
Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial Primer
The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.
Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action
Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.
FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose
Your daily dose of the clinical news you may have missed.
Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials
Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.
FDA Approves Journavx, First-in-Class Nonopioid Analgesic for Moderate-to-Severe Acute Pain
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.
5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life
Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
Furosemide Fails to Reduce Risk of Dangerous de novo Postpartum Hypertension: New Research
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.
Tool Predicts Age at Cognitive Impairment, Dementia Onset: Daily Dose
PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial
Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.
Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial
Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.
Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study
The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.
High-Dose Semaglutide Linked to Increased Weight Loss: Daily Dose
FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD
This newest approval established Ozempic as the most broadly indicted GLP-1 RA in its class.
Alzheimer Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET
Bariatric Surgery Lowers Risk of Liver Complications in Patients with Cirrhosis, Obesity
Metabolic surgery reduced major adverse liver outcomes in people with compensated cirrhosis and obesity by 72%, according to new data.
Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Fall Risk Near End of Life in COPD / image credit ©Toa555/shutterstock.com")
